China’s pharmaceutical regulatory authority has approved a new mRNA vaccine targeting Epstein-Barr virus (EBV) positive tumors for Phase I clinical trials.
Developed by Chengdu-based WestGene Biopharma in Sichuan Province, the vaccine had previously received approval from the US Food and Drug Administration in May, as reported by Chinese state-run Xinhua News.
The vaccine has already shown promise in early trials for nasopharyngeal carcinoma and lymphoma, both of which are cancers linked to EBV—a Group-I carcinogen associated with over 10 types of cancer, including gastric cancer.
WestGene Biopharma plans to conduct additional clinical trials to further explore the vaccine’s potential in advancing tumor immunotherapy.
